RE:Coverage updates?
Paradigm Capital reissued their buy rating on shares of ProMetic Life Sciences (TSE:PLI) in a report released on Monday morning, AnalystRatingsNetwork.com reports. Paradigm Capital currently has a C$3.75 target price on the stock. In other ProMetic Life Sciences news, Director Kurt Stefan Victor Clulow bought 153,400 shares of the companys stock in a transaction on Tuesday, September 29th. The shares were bought at an average cost of C$1.42 per share, for a total transaction of C$217,889.36. Also, insider Patrick Sartore sold 122,736 shares of the stock in a transaction dated Wednesday, July 15th. The stock was sold at an average price of C$2.30, for a total transaction of C$282,722.38. PLI has been the subject of several other reports. Scotiabank set a C$3.00 target price on shares of ProMetic Life Sciences and gave the company an outperform rating in a report on Thursday, July 9th. Canaccord Genuity dropped their price target on shares of ProMetic Life Sciences to C$3.50 and set a buy rating for the company in a research report on Monday, August 17th. Shares of ProMetic Life Sciences (TSE:PLI) opened at 1.47 on Monday. ProMetic Life Sciences has a 52-week low of $1.39 and a 52-week high of $2.87. The stocks 50 day moving average is $1.85 and its 200 day moving average is $2.27. The stocks market cap is $853.66 million. ProMetic Life Sciences Inc. (TSE:PLI) is a Canada-based biopharmaceutical company. The Company offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. The Company operates through two segments: Therapeutics and Protein Technology. Therapeutics segment is a small molecule drug discovery business. It has lead compounds, namely PBI-4050 indicated for the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. Protein Technology segment contains the financial information of the activities, including BioTherapeutics, Bioseparation and Prion Capture/Pathogen Removal.